Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
395 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 |
| clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | terminated | Phase 1 / Phase 2 | 15 | Worldwide Innovative Network AssociationOTHER | 4 | Dec 18, 2023 | clinicaltrials |
| NCT05088889 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | unknown | Phase 1 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02718911 | A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 72 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 16, 2023 | clinicaltrials |
| NCT04729205 | Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies | terminated | Phase 1 | 9 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT00458653 | Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma | completed | Phase 1 | 45 | Beth Israel Deaconess Medical CenterOTHER | 2 | Jun 22, 2023 | clinicaltrials |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | terminated | Phase 1 | 12 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 6 | Jun 13, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT03507699 | Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer | completed | Phase 1 | 19 | Sheba Medical CenterOTHER_GOV | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04991740 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | completed | Phase 1 | 39 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | withdrawn | Phase 1 | 0 | HutchmedINDUSTRY | 7 | Feb 21, 2023 | clinicaltrials |
| NCT02829099 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | completed | Phase 1 | 95 | Janssen Research & Development, LLCINDUSTRY | 2 | Oct 6, 2022 | clinicaltrials |
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT01062399 | Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme(RTOG 0913) | completed | Phase 1 / Phase 2 | 279 | Radiation Therapy Oncology GroupNETWORK | 3 | Jun 9, 2022 | clinicaltrials |
| NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 19 | Can-Fite BioPharmaINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT02659020 | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma(ANNOUNCE 2) | completed | Phase 1 / Phase 2 | 310 | Eli Lilly and CompanyINDUSTRY | 10 | May 9, 2022 | clinicaltrials |
| NCT03876106 | A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions | completed | Phase 1 | 10 | Lutris Pharma Ltd.INDUSTRY | 2 | Apr 6, 2022 | clinicaltrials |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | completed | Phase 1 | 283 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 29, 2022 | clinicaltrials |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | terminated | Phase 1 | 6 | Oncopeptides ABINDUSTRY | 9 | Mar 28, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT02737475 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 166 | Bristol-Myers SquibbINDUSTRY | 6 | Jan 25, 2022 | clinicaltrials |
| NCT03823989 | Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients | completed | Phase 1 | 18 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
| NCT04990739 | Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | MetaboMed IncOTHER | 2 | Dec 17, 2021 | clinicaltrials |
| NCT02938624 | Anti PD-1 Neo-adjuvant Treatment for NSCLC(MK3475-223) | completed | Phase 1 | 28 | Jair Bar, M.D., Ph.D.OTHER_GOV | 1 | Dec 14, 2021 | clinicaltrials |
| NCT01677741 | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | completed | Phase 1 / Phase 2 | 85 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT03364049 | Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Nov 15, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | terminated | Phase 1 | 8 | AbbVieINDUSTRY | 7 | Jul 26, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT02740270 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | completed | Phase 1 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 21, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT01324479 | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | completed | Phase 1 | 131 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 19, 2020 | clinicaltrials |
| NCT03081494 | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 11, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03591276 | Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer(KEYDOX) | recruiting | Phase 1 / Phase 2 | 15 | Shaare Zedek Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials